Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01058993 · ClinicalTrials.gov registry record · Phase 1
AMD 3100 for Treatment of Myelokathexis
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01058993 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 6 participants.
The verdict
NCT01058993, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an initial study to determine if CXCR4 inhibitor AMD 3100 or plerixafor may be a potential treatment for neutropenia due to CXCR4 mutations, the myelokathexis or WHIM (warts, hypogammaglobulinemia, immunodeficiency and myelokathexis) syndrome. This is the initial study of this concept and will involve up to 6 patients to receive increasing doses of plerixafor administered subcutaneously or on an alternate day basis. It is unknown if these patients will be highly sensitive to a blockade of CXCR4 activity and release more white blood cells than normal volunteers or cancer patients given the same dose of this drug. Therefore doses will begin at a level 12 fold less than currently used to mobilize stem cells and will be increased stepwise to achieve an acceptable circulating level of neutrophils.
Interventions
- DRUG AMD3100 or plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01058993
The ClinicalTrials.gov registry entry for NCT01058993 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMD3100 or plerixafor is the first listed.
NCT01058993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01058993 about?
NCT01058993 is a clinical study titled "AMD 3100 for Treatment of Myelokathexis". This is an initial study to determine if CXCR4 inhibitor AMD 3100 or plerixafor may be a potential treatment for neutropenia due to CXCR4 mutations, the myelokathexis or WHIM (warts, hypogammaglobulinemia, immunodeficiency and myelokathexis) syndrome. This is the initial study of this concept and wi...
What is the current status of trial NCT01058993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2010-10. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01058993?
The interventions under investigation include: AMD3100 or plerixafor (DRUG).
Who is sponsoring clinical trial NCT01058993?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.